Forty researchers, executives, and government officials met during the 2005 RSNA meeting to address a key barrier to using medical imaging as a surrogate measure of therapeutic response: variability.
Forty researchers, executives, and government officials met during the 2005 RSNA meeting to address a key barrier to using medical imaging as a surrogate measure of therapeutic response: variability.
Ideally, in drug testing, all components are constant except for changes associated with disease therapy response. The Reference Image Database to Evaluate Response (RIDER) project aims to eliminate variability in proprietary commercial and academic software used in change analysis. Those attending the meeting were briefed about the need for community-wide adoption of the RIDER's Web-based system to assure uniformity in evaluating the performance of change analysis software.
The RIDER project will initially focus on CT-based lung cancer screening and diagnosis, according to Laurence P. Clarke, Ph.D., a branch chief in the National Cancer Institute's imaging program. To aid calibration of their software, researchers will have online access to serial images, annotated by expert physicians, demonstrating tumor volume and other changes in response to treatments over time. The objective is uniform measurement among modalities and sites, making comparisons between facilities possible.
"When measuring drug response, you don't want your tools to be the source of uncertainty," Clarke said.
The NCI, the Institute for Biomedical Imaging and Biomedical Engineering, and the Cancer Research and Prevention Foundation are funding the RIDER project. Collaborators include the RSNA, the American College of Radiology, and the National Institute of Standards and Technology.
One of the aims of the RIDER project is to enable industry and academia to develop, test, and compare semiautomated and automated software tools for change analysis. The NCI eventually wants to combine the RIDER with larger image database initiatives such as the Lung Image Database Consortium (LIDC).
Future public meetings, coordinated by the foundation for the National Institutes of Health, will solicit industry interest and include development of a public-private partnership to fund the RIDER Web site. A final version of the calibration tool will be completed in about two years, Clarke said.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.